CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 78.1% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
US English

Trade Tonix Pharmaceuticals Holding Corp. - TNXP CFD

0.40
5.26%
  • Summary
  • Historical Data
  • Events
  • Income Statement
  • Balance Sheet
  • Cash Flow
Trading сonditions
Spread 0.05
Long position overnight fee

Long position overnight fee


Margin. Your investment $1,000.00
Overnight fee -0.026179 %
Charges from full value of position ($-4.97)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
-0.026179%
Short position overnight fee

Short position overnight fee


Margin. Your investment $1,000.00
Overnight fee 0.003957 %
Charges from full value of position ($0.75)
Trade size with leverage ~ $20,000.00
Money from leverage ~ $19,000.00

Go to platform
0.003957%
Overnight fee time 21:00 (UTC)
Min traded quantity 1
Currency USD
Margin 5%
Stock exchange United States of America
Commission on trade 0%

*Information provided by Capital.com

Tonix Pharmaceuticals Holding Corp ESG Risk Ratings

High Medium Low Negligible

‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.

More ESG coverage

Key Stats
Prev. Close* 0.38
Open* 0.39
1-Year Change* -2.5%
Day's Range* 0.39 - 0.4
52 wk Range 0.27-8.31
Average Volume (10 days) 2.04M
Average Volume (3 months) 30.75M
Market Cap 15.83M
P/E Ratio -100.00K
Shares Outstanding 58.61M
Revenue 3.99M
EPS -11.21
Dividend (Yield %) N/A
Beta 2.26
Next Earnings Date Mar 11, 2024

All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com

  • Last Week
  • Last Month
  • Last Year
  • Last two Years
  • Max
  • Daily
  • Weekly
  • Monthly
Date Close Change Change (%) Open High Low
Jan 3, 2024 0.40 0.01 2.56% 0.39 0.40 0.39
Jan 2, 2024 0.38 0.00 0.00% 0.38 0.40 0.37
Dec 28, 2023 0.38 -0.01 -2.56% 0.39 0.39 0.38
Dec 27, 2023 0.39 0.00 0.00% 0.39 0.39 0.39
Dec 26, 2023 0.38 0.00 0.00% 0.38 0.38 0.38
Dec 21, 2023 0.38 -0.02 -5.00% 0.40 0.40 0.38
Dec 20, 2023 0.39 -0.22 -36.07% 0.61 0.64 0.38
Dec 19, 2023 0.58 -0.08 -12.12% 0.66 0.66 0.51
Dec 18, 2023 0.65 0.07 12.07% 0.58 0.66 0.57
Dec 15, 2023 0.56 0.05 9.80% 0.51 0.56 0.50
Dec 14, 2023 0.50 0.09 21.95% 0.41 0.50 0.41
Dec 13, 2023 0.40 0.01 2.56% 0.39 0.40 0.39
Dec 12, 2023 0.39 0.01 2.63% 0.38 0.39 0.38
Dec 11, 2023 0.38 -0.01 -2.56% 0.39 0.39 0.38
Dec 8, 2023 0.38 0.00 0.00% 0.38 0.39 0.38
Dec 7, 2023 0.39 -0.04 -9.30% 0.43 0.43 0.39
Dec 6, 2023 0.44 -0.03 -6.38% 0.47 0.47 0.40
Dec 5, 2023 0.45 -0.02 -4.26% 0.47 0.48 0.45
Dec 4, 2023 0.45 -0.06 -11.76% 0.51 0.53 0.44
Dec 1, 2023 0.50 0.00 0.00% 0.50 0.50 0.49

Tonix Pharmaceuticals Holding Corp. Events

Time (UTC) Country Event
Friday, May 3, 2024

Time (UTC)

15:00

Country

US

Event

Tonix Pharmaceuticals Holding Corp Annual Shareholders Meeting
Tonix Pharmaceuticals Holding Corp Annual Shareholders Meeting

Forecast

-

Previous

-
Monday, May 6, 2024

Time (UTC)

12:30

Country

US

Event

Q1 2024 Tonix Pharmaceuticals Holding Corp Earnings Release
Q1 2024 Tonix Pharmaceuticals Holding Corp Earnings Release

Forecast

-

Previous

-
View all events
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total revenue 0 0 0 0 0
Total Operating Expense 112.091 92.312 50.511 28.828 26.322
Selling/General/Admin. Expenses, Total 30.215 23.474 14.354 10.636 8.764
Research & Development 81.876 68.838 36.157 18.192 17.558
Operating Income -112.091 -92.312 -50.511 -28.828 -26.322
Interest Income (Expense), Net Non-Operating 1.873 0.025 0.048 0.21 0.233
Net Income Before Taxes -110.218 -92.287 -50.463 -28.618 -26.089
Net Income After Taxes -110.218 -92.287 -50.463 -28.618 -26.089
Net Income Before Extra. Items -110.218 -92.287 -50.463 -28.618 -26.089
Net Income -110.218 -92.287 -50.463 -28.618 -26.089
Income Available to Common Excl. Extra. Items -116.877 -92.287 -52.174 -31.092 -29.355
Income Available to Common Incl. Extra. Items -116.877 -92.287 -52.174 -31.092 -29.355
Diluted Net Income -116.877 -92.287 -52.174 -31.092 -29.355
Diluted Weighted Average Shares 5.71825 1.80108 0.47296 0.00804 0.00055
Diluted EPS Excluding Extraordinary Items -20.4393 -51.2399 -110.314 -3865.8 -53623
Diluted Normalized EPS -20.4393 -51.2399 -110.314 -3865.8 -53623
Total Extraordinary Items
Dividends per Share - Common Stock Primary Issue
Total Adjustments to Net Income -6.659 0 -1.711 -2.474 -3.266
Jun 2023 Mar 2023 Dec 2022 Sep 2022 Jun 2022
Total revenue 0 0 0 0 0
Total Operating Expense 29.002 33.902 32.728 29.591 23.336
Selling/General/Admin. Expenses, Total 7.026 7.391 8.054 7.39 6.757
Research & Development 21.976 26.511 24.674 22.201 16.579
Operating Income -29.002 -33.902 -32.728 -29.591 -23.336
Interest Income (Expense), Net Non-Operating 0.646 0.897 1.048 0.61 0.196
Net Income Before Taxes -28.356 -33.005 -31.68 -28.981 -23.14
Net Income After Taxes -28.356 -33.005 -31.68 -28.981 -23.14
Net Income Before Extra. Items -28.356 -33.005 -31.68 -28.981 -23.14
Net Income -28.356 -33.005 -31.68 -28.981 -23.14
Income Available to Common Excl. Extra. Items -28.356 -33.005 -34.084 -28.981 -27.395
Income Available to Common Incl. Extra. Items -28.356 -33.005 -34.084 -28.981 -27.395
Diluted Net Income -28.356 -33.005 -34.084 -28.981 -27.395
Diluted Weighted Average Shares 10.5871 10.1365 9.88108 6.71109 3.5847
Diluted EPS Excluding Extraordinary Items -2.67835 -3.25607 -3.44942 -4.31838 -7.6422
Dividends per Share - Common Stock Primary Issue 0 0 0 0
Diluted Normalized EPS -2.67835 -3.25607 -3.44942 -4.31838 -7.6422
Total Adjustments to Net Income 0 -2.404 0 -4.255
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Total Current Assets 130.777 189.049 87.989 13.948 26.056
Cash and Short Term Investments 120.229 178.66 77.068 11.249 25.034
Cash & Equivalents 120.229 178.66 77.068 11.249 25.034
Short Term Investments
Prepaid Expenses 10.548 10.389 10.921 2.699 1.022
Total Assets 225.69 240.9 98.183 14.558 26.319
Property/Plant/Equipment, Total - Net 94.529 51.472 9.829 0.39 0.043
Property/Plant/Equipment, Total - Gross 96.182 51.872 10.179 0.713 0.34
Accumulated Depreciation, Total -1.653 -0.4 -0.35 -0.323 -0.297
Intangibles, Net 0.12 0.12 0.12 0.12
Other Long Term Assets, Total 0.384 0.259 0.245 0.1 0.1
Total Current Liabilities 18.18 21.716 9.819 5.135 2.655
Accounts Payable 8.068 13.282 4.598 3.07 1.404
Accrued Expenses 6.18 4.929 2.6 1.042 0.614
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 18.508 22.183 10.535 5.141 2.655
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 0.328 0.467 0.716 0.006 0
Total Equity 207.182 218.717 87.648 9.417 23.664
Common Stock 0.076 0.496 0.206 0.009 0.003
Additional Paid-In Capital 677.311 578.133 355.037 226.524 212.154
Retained Earnings (Accumulated Deficit) -470.038 -359.82 -267.533 -217.07 -188.452
Other Equity, Total -0.167 -0.092 -0.062 -0.046 -0.041
Total Liabilities & Shareholders’ Equity 225.69 240.9 98.183 14.558 26.319
Total Common Shares Outstanding 12.2366 2.48123 1.03004 0.04266 0.00163
Other Current Liabilities, Total 3.932 3.505 2.621 1.023 0.637
Sep 2023 Jun 2023 Mar 2023 Dec 2022 Sep 2022
Total Current Assets 31.337 51.329 83.726 130.777 151.139
Cash and Short Term Investments 6.914 25.617 71.975 120.229 139.978
Cash & Equivalents 6.914 25.617 71.975 120.229 139.978
Prepaid Expenses 9.544 12.012 11.751 10.548 11.161
Total Assets 139.282 159.736 179.088 225.69 242.646
Property/Plant/Equipment, Total - Net 95.947 96.93 94.977 94.529 91.147
Property/Plant/Equipment, Total - Gross 100.342 100.397 97.523 96.182 91.964
Accumulated Depreciation, Total -4.395 -3.467 -2.546 -1.653 -0.817
Intangibles, Net 9.982 10.22
Other Long Term Assets, Total 1.051 0.292 0.385 0.384 0.36
Total Current Liabilities 17.733 18.442 13.073 18.18 13.34
Accounts Payable 7.799 7.673 8.016 8.068 4.556
Accrued Expenses 9.934 10.769 5.057 10.112 8.784
Notes Payable/Short Term Debt 0 0 0 0 0
Total Liabilities 18.449 19.273 13.661 18.508 13.722
Total Long Term Debt 0 0 0 0 0
Other Liabilities, Total 0.716 0.831 0.588 0.328 0.382
Total Equity 120.833 140.463 165.427 207.182 228.924
Common Stock 0.018 0.011 0.064 0.076 0.053
Additional Paid-In Capital 694.371 686.025 682.566 677.311 667.389
Retained Earnings (Accumulated Deficit) -573.336 -545.361 -516.992 -470.038 -438.358
Other Equity, Total -0.22 -0.212 -0.211 -0.167 -0.16
Total Liabilities & Shareholders’ Equity 139.282 159.736 179.088 225.69 242.646
Total Common Shares Outstanding 17.7623 10.7623 10.19 12.2366 8.53144
Redeemable Preferred Stock
Other Current Assets, Total
Total Inventory 13.317 13.7
Goodwill, Net 0.965 0.965
Total Receivables, Net 1.562
Accounts Receivable - Trade, Net 1.562
  • Annual
  • Quarterly
2022 2021 2020 2019 2018
Net income/Starting Line -110.218 -92.287 -50.463 -28.618 -26.089
Cash From Operating Activities -98.053 -75.557 -48.566 -26.683 -23.971
Cash From Operating Activities 1.253 0.05 0.027 0.026 0.054
Non-Cash Items 10.914 10.899 4.236 1.457 1.627
Changes in Working Capital -0.002 5.781 -2.366 0.452 0.437
Cash From Investing Activities -48.147 -35.307 -8.564 -0.017 -0.006
Capital Expenditures -48.147 -35.307 -8.564 -0.017 -0.006
Other Investing Cash Flow Items, Total 0
Cash From Financing Activities 87.844 212.487 123.105 12.919 23.539
Issuance (Retirement) of Stock, Net 87.844 212.487 123.105 12.919 23.539
Foreign Exchange Effects -0.074 -0.031 -0.016 -0.004 -0.013
Net Change in Cash -58.43 101.592 65.959 -13.785 -0.451
Cash Taxes Paid 0 0.082
Mar 2023 Dec 2022 Sep 2022 Jun 2022 Mar 2022
Net income/Starting Line -33.005 -110.218 -78.538 -49.557 -26.417
Cash From Operating Activities -32.911 -98.053 -75.752 -52.217 -31.046
Cash From Operating Activities 0.893 1.253 0.417 0.165 0.063
Non-Cash Items 2.794 10.914 8.198 5.433 2.62
Changes in Working Capital -3.593 -0.002 -5.829 -8.258 -7.312
Cash From Investing Activities -3.799 -48.147 -43.476 -34.656 -20.217
Capital Expenditures -3.799 -48.147 -43.476 -34.656 -20.217
Cash From Financing Activities -11.5 87.844 80.615 85.24 13.063
Issuance (Retirement) of Stock, Net -11.5 87.844 80.615 85.24 13.063
Foreign Exchange Effects -0.043 -0.074 -0.069 -0.049 -0.025
Net Change in Cash -48.253 -58.43 -38.682 -1.682 -38.225

Trading calculator

Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).

Trade commission
0
  • 1:1
Leverage
1:1
  • 20
  • 100
  • 500
  • 1000
  • 10000
Investment
Trade size (Leverage x Investement):
Open

Close

Short Long

For the avoidance of doubt, this calculation does not include the costs of holding a position overnight (for which there will be additional charges)

Tonix Pharmaceuticals Holding Corp. Company profile

Tonix Pharmaceuticals Holding Corp. (TNXP) is a clinical-stage biopharmaceutical company that focuses on understanding diseases and developing innovative therapies with the potential to address unmet needs. 

Headquartered in Chatham, New Jersey, Tonix Pharma was founded in 2007 with the idea of developing a diverse yet curated portfolio of small molecule drugs across various therapeutic areas, like the central nervous system (CNS), immunology, infectious disease and rare diseases. With a significant investment in in-house research and development and manufacturing, Tonix Pharma accelerates the drug development and reachability timeline and can respond immediately in case of an infectious disease breakout. 

The company’s CNS portfolio comprises TNX-102 SL (Confirmatory Phase 3) for Fibromyalgia. Drugs in phase 2 development are TNX-102 SL for Posttraumatic Stress Disorder (PTSD), TNX-102 SL for long Covid, TNX-1300 for cocaine overdose and TNX-1900 for chronic migraine. It also has two drugs in the preclinical phase: TNX-1500 for organ transplant rejection/autoimmune disorders and TNX-1700 for gastric and colorectal cancers. 

Pathogenic infections like smallpox and monkeypox have been a core area of focus for Tonix for a long time, however, the Covid-19 outbreak pushed the company to focus on rapid preparedness to combat infectious diseases. The company has the TNX-1840/1850 Covid-19 vaccine, TNX-3500 Covid-19 antiviral, TNX-3600 Covid-19 therapeutic and TNX-801 smallpox and monkeypox vaccine under development and in preclinical stages. 

Tonix’s rare disease portfolio includes TNX-2900 for Prader-Willi syndrome, which is in the preclinical stage.

Tonix shares began trading under the ticker symbol ‘TNXP’ on the Nasdaq Capital Market in August 2013.

Industry: Bio Therapeutic Drugs

26 Main Street, Suite 101
CHATHAM
NEW JERSEY 07928
US

Income Statement

  • Annual
  • Quarterly

News

A way forward: a roundup of recent central bank decisions

Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.

12:47, 22 March 2024

Bank of Japan Preview: will the BOJ end negative interest rates?

The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.

08:44, 18 March 2024

Higher CPI leaves traders unfazed as US equities continue to build momentum

The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.

12:42, 15 March 2024

Four reasons why Bitcoin is surging to record highs

Bitcoin has surged to record highs. We discuss the four factors pushing Bitcoin higher and analyse the technicals of the cryptocurrency’s technicals.

10:18, 14 March 2024

China’s National People’s Congress: The markets have again been left wanting more

China’s National People’s Congress (NPC) is underway, and the markets have so far been disappointed by what’s been delivered by the country’s central government. We look at some of the significant takeaways from the event, discuss China’s current economic conditions, and analyse the China A50.

08:23, 8 March 2024
Facade on the Federal Reserve Building in Washington DC

Central Banks: which one will cut first?

Central banks dominate the calendar in March and markets try to anticipate which one will be the first one to cut

13:14, 6 March 2024

Nvidia (NVDA) confronts high expectations for Q4 results

Nvidia is arguably the hottest company on the planet. The company reports its Q4 results after the closing bell on Wednesday, the 21st of February. We preview what to expect from Nvidia’s earnings and analyse the technicals of its stock price.

12:13, 20 February 2024

People also watch

BTC/USD

70,577.75 Price
-0.440% 1D Chg, %
Long position overnight fee -0.0616%
Short position overnight fee 0.0137%
Overnight fee time 21:00 (UTC)
Spread 106.00

US100

18,249.40 Price
-0.200% 1D Chg, %
Long position overnight fee -0.0262%
Short position overnight fee 0.0040%
Overnight fee time 21:00 (UTC)
Spread 7.0

Gold

2,233.43 Price
+1.740% 1D Chg, %
Long position overnight fee -0.0188%
Short position overnight fee 0.0106%
Overnight fee time 21:00 (UTC)
Spread 0.80

XRP/USD

0.63 Price
-1.100% 1D Chg, %
Long position overnight fee -0.0753%
Short position overnight fee 0.0069%
Overnight fee time 21:00 (UTC)
Spread 0.01168

Still looking for a broker you can trust?

Join the 580.000+ traders worldwide that chose to trade with Capital.com

1. Create & verify your account 2. Make your first deposit 3. You’re all set. Start trading